Catalog No.
RHG17603
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q08722
Applications
ELISA, FCM, IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3R71
STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis., PMID:40529368
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014
SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma., PMID:40523887
Mechanism of EC-EXOs-Derived THBS3 Targeting CD47 to Regulate BMSCs Differentiation to Ameliorate Bone Loss., PMID:40514348
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351
Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521
Efferocytosis and its role in rheumatic diseases., PMID:40452369
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525
CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082
The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682
Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617
CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148
Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156
Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma., PMID:40347051
Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT., PMID:40332470
Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602
TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254
Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109
Engineered Bacterial Outer Membrane Vesicles Hitchhiking on Neutrophils for Antibody Drug Delivery to Enhance Postoperative Immune Checkpoint Therapy., PMID:40287972
Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489
CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910
CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion., PMID:40255405
Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation., PMID:40251154
Successful targeting of multidrug-resistant tumors with bispecific antibodies., PMID:40248904
Nanobody Engineered and Photosensitiser Loaded Bacterial Outer Membrane Vesicles Potentiate Antitumour Immunity and Immunotherapy., PMID:40240911
The "don't eat me" signal CD47 is associated with microglial phagocytosis defects and autism-like behaviors in 16p11.2 deletion mice., PMID:40238451
Molecular and Immunometabolic Landscape of Erythrophagocytosis-induced Ferroptosis., PMID:40231500
An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272
High-Throughput Screening on Primary Tumor-Associated Microglia and Macrophages Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Partners for Immunotherapy in Glioblastoma., PMID:40196519
Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects., PMID:40187444
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)., PMID:40175391
Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells., PMID:40147800
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179
Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy., PMID:40138400
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy., PMID:40136470
Regulating islet stress responses through CD47 activation., PMID:40133488
CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery., PMID:40087866
Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile., PMID:40084615
For research use only. Not for human or drug use.
